Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Re­genxbio, a small li­cen­sor of gene ther­a­py vi­ral vec­tors spun out from the Uni­ver­si­ty of Penn­syl­va­nia, is now find­ing it­self in the mid­dle of some ma­jor league patent fights.

In ad­di­tion to a patent suit with Sarep­ta Ther­a­peu­tics from last Sep­tem­ber, No­var­tis is now try­ing to push its small­er part­ner out of the way. The Swiss bio­phar­ma li­censed Re­genxbio’s AAV9 vec­tor for its $2.1 mil­lion spinal mus­cu­lar at­ro­phy ther­a­py Zol­gens­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER